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Human malignant tumours have developed a variety of effective molecular strategies which 23 
allow them to escape host immune surveillance leading to a disease progression. This 24 
includes haematological malignancies such as acute myeloid leukaemia (AML), a blood/bone 25 
marrow cancer originating from self-renewing myeloid cell precursors which rapidly 26 
becomes systemic. AML cells are capable of escaping immune attack despite being 27 
permanently exposed to host immune cells including cytotoxic T cells (CTCs) and natural 28 
killer (NK) cells1. AML cells successfully implement biochemical mechanisms which allow 29 
them to inactivate cytotoxic lymphoid cells (NK cells and CTCs) upon direct contact as well 30 
as at a distance2 ,Q WKLV FDVH WKH\ QRW RQO\ ³ILJKW EDFN´ DJDLQVW LPPXQH FHOOV EXW DOVR31 
effectively prevent the actual process of cytotoxic immune attack. In this work we will 32 
discuss several important biochemical mechanisms which allow AML cells to form 33 
immunological synapses with cytotoxic lymphoid cells and also comprehensively inactivate 34 
anti-cancer immunity at a distance.  35 
T helper (Th) type cells generate and secrete interleukin-2 (IL-2), a stimulatory cytokine 36 
which triggers activation of NK cells as well as CTCs3. Upon activation, these cytotoxic 37 
lymphoid cells become capable of attacking malignant (AML for example) cells delivering 38 
the proteolytic enzyme granzyme B into them. Granzyme B itself can directly activate one of 39 
the key apoptotic enzymes, caspase-3. However, granzyme B performs cleavage of the pro-40 
apoptotic protein Bid, forming its active form tBid which negatively impacts on 41 
mitochondrial function, inducing release of cytochrome c, one of the major components of 42 
electron respiratory chain. Cytochrome c interacts with apoptotic protease activating factor-1 43 
(Apaf-1) and pro-caspase-9 thus forming an apoptosome, which induces programmed death 44 
of target cell2.  45 
It has become evident that AML cells are capable of expressing surface proteins such as 46 
programmed death-1 (PD-1) receptor ligands (PD-Ls) 1 and 2 as well as CD86, the ligand of 47 
cytotoxic T-cell antigen 4 (CTLA4)1. T helpers and CTCs/NK cells express PD-1 receptors 48 
on their surface. AML cell surface-based PD-1 ligands 1 and 2 (PD-L(i)) interact with PD-1 49 
on lymphoid cell surfaces. As a result, T helper cells stop producing IL-2 required for the 50 
activation of both CTCs and NK cells. PD-1 signalling attenuates the SURWHLQ NLQDVH & ș51 
(PKC-ș) loop thus preventing activation of transcription factors NF-ț%DQGAP-1, which are 52 
required for IL-2 production4.  53 
On the other hand, the interaction of PD-Ls with PD-1 on the surface of NK cells and CTCs 54 
leads to their rapid inactivation, and, as a result, they lose ability to kill AML cells1. In 55 
addition, AML cells are often capable of expressing the CTLA4 ligand CD86. Interaction of 56 
CD86 with CTLA4 rapidly leads to inactivation of effector T cells1,5.  57 
Thus, one could conclude that CD86 and PD-Ls 1 and 2 are involved in the formation of 58 
immunological synapses with both regulatory and cytotoxic lymphoid cells leading to 59 
downregulation of the biochemical activation of CTCs and NK cells. Direct interaction of 60 
PD-Ls and CD86 with CTCs and NK cells leads to loss of their anti-cancer activities. 61 
Schematically this process is shown in Figure 1.  62 
Recent evidence also demonstrated the ability of AML cells to downregulate the activity of 63 
cytotoxic lymphoid cells through lymphocyte-activation gene 3 (LAG-3), which is a homolog 64 
of CD84. AML cells were reported to induce exhaustion of cytotoxic lymphoid cells through 65 
LAG-3 but detailed mechanisms of this event remain to be elucidated1,5. 66 
Recently, it has become evident that the immune receptor Tim-3 (T cell immunoglobulin and 67 
mucin domain containing protein 3) is involved in protecting AML cells against host immune 68 
surveillance2,6. Tim-3 has a natural ligand galectin-9 (a tandem protein which contains two 69 
receptor-binding domains fused together by a peptide linker) which was suggested to form an 70 
autocrine loop with the receptor7. When present on the cell surface, galectin-9 induces Tim-3 71 
downstream signalling which includes activation of pathways responsible for cell survival7-9. 72 
This first of all includes activation of transcription factor nuclear factor kappa B (NF-kB)7, 73 
translational pathways controlled by mammalian target of rapamycin (mTOR) and hypoxic 74 
signalling required for the adaptation of AML cells to stress conditions and their survival in 75 
general8,9. The Tim-3-galectin-9 complex was also reported to activate the ȕ-catenin pathway 76 
which, together with NF-kB, controls self-renewal of AML cells7. Taken together, one may 77 
conclude that galectin-9 mediates survival signalling through Tim-3 (Figure 2).  78 
Galectin-9 lacks a secretory domain and thus requires a trafficker in order to be taken to the 79 
cell surface and then secreted2,10. We have recently found that AML cells but not healthy 80 
leukocytes express the neuronal receptor latrophilin 1 (LPHN1). LPHN1 is expressed in 81 
haematopoietic stem cells, but disappears upon maturation unless they undergo malignant 82 
transformation into AML cells. Using its natural ligands (for example fibronectin leucine rich 83 
transmembrane protein 3, FLRT3), LPHN1 facilitates exocytosis of Tim-3-galectin-9, which 84 
then triggers cell survival signalling. However, Tim-3 either on its own or in complex with 85 
galectin-9 can also be proteolytically shed from the surface of AML cells thus leading to 86 
secretion of both proteins. Galectin-9 interacts with NK cells and CTCs (most likely though 87 
Tim-3)2. This leads to impairing of cytotoxic activity of NK cells and killing of CTCs. 88 
Interestingly, NK cells produce interferon gamma (IFN-Ȗ LQ UHVSRQVH WR VWLPXODWLRQ ZLWK89 
galectin-9. IFN-ȖLQGXces the activation of indoleamine 2,3-dioxygenase (IDO1), an enzyme 90 
converting L-tryptophan into formyl-L-kynurenine, which is then degraded into L-kynurenine 91 
and released12. L-kynurenine impairs the cytotoxic activity of NK cells2.  92 
Intriguingly, IFN-ȖLV also known to induce the expression of PD-Ls 13, which might further 93 
promote the ability of AML cells to protect themselves against host immune surveillance.  94 
Soluble Tim-3 released by AML cells is capable of downregulating IL-2 secretion by Th cells 95 
acting via a receptor which remains to be identified2. This prevents the activation of cytotoxic 96 
lymphoid cells. Importantly, the secretion of Tim-3 and galectin-9 allows AML cells to 97 
supress cytotoxic lymphoid cells at a distance thus minimising direct interaction with them. 98 
7KLVDOORZV$0/FHOOVWR³IRFXVRQ´VHOI-renewal thus leading to rapid disease progression. 99 
The functioning of the Tim-3-galectin-9 secretory and signalling pathway in AML cells is 100 
summarised in Figure 2. 101 
Importantly, stress associated with the events described above leads to release of high 102 
mobility group box 1 (HMGB1) protein by AML cells which finally triggers production of 103 
interleukin 1 beta (IL-ȕ E\ KHDOWK\ OHXNRF\WHV14. IL-ȕ ZDV UHSRUWHG WR LQGXFH WKH104 
expression and production of stem cell factor (SCF) by epithelial cells via mTOR pathway 105 
and hypoxic signalling15. SCF is a major hematopoietic growth factor that controls the AML 106 
progression thus becoming highly oncogenic15. In such a way, AML cells employ body 107 
systems to produce factors required for their proliferation/disease progression14,15. 108 
 109 
Taken together, it is clear that AML cells implement comprehensive mechanisms in order to 110 
escape immune surveillance and progress the disease. Pharmacological targeting of the 111 
biochemical pathways responsible for immune escape will enable the human immune system 112 
to potentially cure AML and thus avoid aggressive chemotherapy and bone marrow 113 
transplantation. Therefore, design and development of new strategies for anti-AML 114 
immunotherapy are a major focus for current applied AML research. It is also vital to 115 
investigate whether other cancers operate similar mechanisms since certain solid tumours 116 
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Figure Legends 172 
Figure 1. AML cells supress IL-2 production and the activity of cytotoxic lymphoid cells 173 
via PD-1 and CTLA4 receptors  174 
 175 
 176 
Figure 2. The Tim-3-galectin-9 pathway regulates both intracellular AML cell survival 177 
signalling and immune escape.  178 
 179 
